Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

Background: Intensifying infliximab therapy is often practiced in Crohn's disease (CD) patients losing response to the drug but there are no data if halving the interval is superior to doubling the dose. We aimed to assess the efficacy of infliximab dose intensification by interval-halving compared with dose-doubling.

Methods: A multicenter retrospective study of CD patients losing response to infliximab was undertaken.